Products
Platform
Research
Market
Learn
IPO
Compare Mutual Funds
Fund Comparison
Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Select a Mutual Fund
Fund Details
Risk | Very High | - |
Rating | 5.0 | - |
Min SIP Amount | ₹100 | - |
Expense Ratio | 1.87 | - |
NAV | ₹40.25 | - |
Fund Started | 25 Jun 2018 | - |
Fund Size | ₹6437.36 Cr | - |
Exit Load | Exit load of 1% if redeemed within 15 days. | - |
Risk
Very High
-
Rating
5.0
-
Min SIP Amount
₹100
-
Expense Ratio
1.87
-
NAV
₹40.25
-
Fund Started
25 Jun 2018
-
Fund Size
₹6437.36 Cr
-
Exit Load
Exit load of 1% if redeemed within 15 days.
-
Returns
1 Year | 4.57% | - |
3 Year | 26.61% | - |
5 Year | 19.34% | - |
1 Year
4.57%
-
3 Year
26.61%
-
5 Year
19.34%
-
Holding Analysis
Equity | 97.10% | - |
Cash | 2.90% | - |
Equity
97.10%
-
Cash
2.90%
-
Top Holdings
Top 10 Holdings |
| - |
Top 10 Holdings
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 11.88% |
Dr. Reddy's Laboratories Ltd. | 9.42% |
Divi's Laboratories Ltd. | 8.50% |
Aurobindo Pharma Ltd. | 7.62% |
Cipla Ltd. | 6.61% |
Lupin Ltd. | 5.40% |
Alkem Laboratories Ltd. | 3.98% |
Biocon Ltd. | 3.28% |
Mankind Pharma Ltd. | 2.79% |
Zydus Lifesciences Ltd. | 2.67% |
-
Fund Manager
Name | Dharmesh Kakkad | - |
Start Date | 23 Feb 2021 | - |
Name
Dharmesh Kakkad
-
Start Date
23 Feb 2021
-
About Fund
Description | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. | - |
Launch Date | 25 Jun 2018 | - |
Description
The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies.
-
Launch Date
25 Jun 2018
-